FIELD: chemistry.
SUBSTANCE: invention relates to a crystalline form of a compound of formula (I), where crystalline form is crystalline form A of compound of formula (I), which on powder X-ray diffraction pattern obtained using Cu-Kα-radiation, is characterized by diffraction peaks at following values 2θ 12.1 ± 0.200°, 16.1 ± 0.200°, 18.5 ± 0.200°, 20.2 ± 0.200°, 21.3 ± 0.200° and 23.0 ± 0.200°. Invention also relates to a pharmaceutical composition for treating thrice-negative breast cancer containing a therapeutically effective amount of a crystalline form of the compound of formula (I) and a pharmaceutically acceptable carrier.
EFFECT: crystalline form of the compound of formula (I) for use as an inhibitor with respect to cIAP1, having such properties as pharmacokinetics, bioavailability, low hygroscopicity, high stability.
8 cl, 3 dwg, 8 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BICYCLIC HETEROCYCLIC COMPOUNDS AND USE THEREOF IN THERAPY | 2014 |
|
RU2696310C1 |
| CRYSTALLINE OR AMORPHOUS FORM OF FXR AGONISTS BEING STEROID DERIVATIVES, THEIR PRODUCTION METHOD AND THEIR USE | 2018 |
|
RU2800751C2 |
| COMPOUND OF BRD4 INHIBITOR IN SOLID FORM, METHOD FOR ITS PRODUCTION AND APPLICATION | 2020 |
|
RU2793346C1 |
| INDAZOLE DERIVATIVE SALTS AND THEIR CRYSTALS | 2017 |
|
RU2747399C2 |
| SALTS AND CRYSTALLINE FORMS OF DIAZABENZOFLUORANTHENE COMPOUNDS | 2017 |
|
RU2762189C2 |
| SYK INHIBITOR SALT AND CRYSTALLINE FORM THEREOF | 2019 |
|
RU2818103C2 |
| CRYSTALLINE FGFR4 INHIBITOR AND ITS APPLICATION | 2016 |
|
RU2763328C2 |
| PYRIDO[1,2-A]PYRIMIDONE ANALOG, ITS CRYSTAL FORM, ITS INTERMEDIATE COMPOUND AND METHOD FOR THEIR PREPARATION | 2016 |
|
RU2753696C2 |
| POLYMORPHIC FORM OF DIARYL MACROCYCLE | 2016 |
|
RU2765181C2 |
| SOLID FORMS OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS FOR USE THEREOF | 2016 |
|
RU2743349C2 |
